Trans-resveratrol-mediated inhibition of β-oestradiol conjugation in MCF-7 cells stably expressing human sulfotransferases SULT1A1 or SULT1E1, and human liver microsomes

Xenobiotica

Volumn 39, Issue 1, 2009, Pages 72-79

  Ung, D ^a   Nagar, S ^a  

^a TEMPLE UNIVERSITY   (United States)

Author keywords

Cancer; Glucuronidation; Oestradiol; Proliferation; Resveratrol; Sulfation

Indexed keywords

ESTRADIOL; GLUCURONOSYLTRANSFERASE; RESVERATROL; SULFOTRANSFERASE; SULFOTRANSFERASE 1A1; SULFOTRANSFERASE 1E1; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CELL PROLIFERATION; CELL STRAIN MCF 7; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DISPOSITION; ENZYME INHIBITION; GLUCURONIDATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER MICROSOME; MAMMAL CELL; PROTEIN EXPRESSION; SULFATION;

ARYLSULFOTRANSFERASE; CELL LINE, TUMOR; CELL PROLIFERATION; ESTRADIOL; ESTRADIOL ANTAGONISTS; HUMANS; MICROSOMES, LIVER; STILBENES; SULFOTRANSFERASES;

MAMMALIA;

EID: 61649084453     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250802604082     Document Type: Article

References (30)

1. Adjei A, Weinshilboum R. 2002. Catecholestrogen sulfation: possible role in carcinogenesis. Biochemical and Biophysical Research Communications 292:402-408.
2. Alkharfy KM, Frye RF. 2002. Sensitive liquid chromatographic method using fluorescence detection for the determination of estradiol 3-and 17-glucuronides in rat and human liver microsomal incubations: formation kinetics. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences 774(1):33-38.
3. Aumont V, Krisa S, Battaglia E, Netter P, Richard T, Merillon JM, Magdalou J, Sabolovic N. 2001. Regioselective and stereospecific glucuronidation of trans- and cis-resveratrol in human. Archives of Biochemistry and Biophysics 393(2):281-289.
4. Baur JA, Sinclair DA. 2006. Therapeutic potential of resveratrol: the in vivo evidence. Nature Reviews Drug Discovery 5(6):493-506.
5. Boocock DJ, Faust GE, Patel KR, Schinas AM, Brown VA, Ducharme MP, Booth TD, Crowell JA, Perloff M, Gescher AJ, Steward WP, Brenner DE. 2007. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiology and Biomarkers Prevention 16(6):1246-1252.
6. Cao Z, Li Y. 2004. Potent induction of cellular antioxidants and phase 2 enzymes by resveratrol in cardiomyocytes: protection against oxidative and electrophilic injury. European Journal of Pharmacology 489(1-2):39-48.
7. Cheng Z, Rios GR, King CD, Coffman BL, Green MD, Mojarrabi B, Mackenzie PI, Tephly TR. 1998. Glucuronidation of catechol estrogens by expressed human UDP-glucuronosyltransferases (UGTs) 1A1, 1A3, and 2B7. Toxicology Science 45(1):52-57.
8. Chouinard S, Tessier M, Vernouillet G, Gauthier S, Labrie F, Barbier O, Belanger A. 2006. Inactivation of the pure antiestrogen fulvestrant and other synthetic estrogen molecules by UDP-glucuronosyltransferase 1A enzymes expressed in breast tissue. Molecular Pharmacology 69:908-920.
9. De Santi C, Pietrabissa A, Mosca F, Pacifici GM. 2000a. Glucuronidation of resveratrol, a natural product present in grape and wine, in the human liver. Xenobiotica 30(11):1047-1054.
10. De Santi C, Pietrabissa A, Spisni R, Mosca F, Pacifici GM. 2000b. Sulphation of resveratrol, a natural compound present in wine, and its inhibition by natural flavonoids. Xenobiotica 30(9):857-866.
11. Fisher MB, Campanale K, Ackermann BL, VandenBranden M, Wrighton SA. 2000. In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin. Drug Metabolism and Disposition 28(5):560-566.
12. Furimsky AM, Green CE, Sharp LE, Catz P, Adjei AA, Parman T, Kapetanovic IM, Weinshilboum RM, Iyer LV. 2008. Effect of resveratrol on 17beta-estradiol sulfation by human hepatic and jejunal S9 and recombinant sulfotransferase 1E1. Drug Metabolism and Disposition 36(1):129-136.
13. Gehm BD, Levenson AS, Liu H, Lee EJ, Amundsen BM, Cushman M, Jordan VC, Jameson JL. 2004. Estrogenic effects of resveratrol in breast cancer cells expressing mutant and wild-type estrogen receptors: role of AF-1 and AF-2. Journal of Steroid Biochemistry and Molecular Biology 88(3):223-234.
14. Iwuchukwu OF, Nagar S. 2008. Resveratrol (trans-resveratrol, 3,5,4′-trihydroxy-trans-stilbene) glucuronidation exhibits atypical enzyme kinetics in various protein sources. Drug Metabolism and Disposition 36(2):322-330.
15. Kim YA, Choi BT, Lee YT, Park DI, Rhee SH, Park KY, Choi YH. 2004. Resveratrol inhibits cell proliferation and induces apoptosis of human breast carcinoma MCF-7 cells. Oncology Report 11(2):441-446.
16. Lancon A, Hanet N, Jannin B, Delmas D, Heydel JM, Lizard G, Chagnon MC, Artur Y, Latruffe N. 2007. Resveratrol in human hepatoma HepG2 cells: metabolism and inducibility of detoxifying enzymes. Drug Metabolism and Disposition 35(5):699-703.
17. Lehmann L, Wagner J. 2008. Gene expression of 17beta-estradiol- metabolizing isozymes: comparison of normal human mammary gland to normal human liver and to cultured human breast adenocarcinoma cells. Advances in Experimental Medicine and Biology 617:617-624.
18. Lu R, Serrero G. 1999. Resveratrol, a natural product derived from grape, exhibits antiestrogenic activity and inhibits the growth of human breast cancer cells. Journal of Cell Physiology 179(3):297-304.
19. Miksits M, Maier-Salamon A, Aust S, Thalhammer T, Reznicek G, Kunert O, Haslinger E, Szekeres T, Jaeger W. 2005. Sulfation of resveratrol in human liver: evidence of a major role for the sulfotransferases SULT1A1 and SULT1E1. Xenobiotica 35(12):1101-1119.
20. Murias M, Miksits M, Aust S, Spatzenegger M, Thalhammer T, Szekeres T, Jaeger W. 2008. Metabolism of resveratrol in breast cancer cell lines: impact of sulfotransferase 1A1 expression on cell growth inhibition. Cancer Letters 261(2):172-182.
21. Nagar S, Remmel RP. 2006. Uridine diphosphoglucuronosyltransferase pharmacogenetics and cancer. Oncogene 25(11):1659-1672.
22. Nagar S, Remmel R, Hebbel R, Zimmerman C. 2004. Metabolism of morphine is altered in liver microsomes of sickle cell transgenic mice. Drug Metabolism and Disposition 32:98-104.
23. Nagar S, Walther S, Blanchard RL. 2006. Sulfotransferase (SULT) 1A1 polymorphic variants *1, *2, and *3 are associated with altered enzymatic activity, cellular phenotype, and protein degradation. Molecular Pharmacology 69(6):2084-2092.
24. Otake Y, Nolan AL, Walle UK, Walle T. 2000. Quercetin and resveratrol potently reduce estrogen sulfotransferase activity in normal human mammary epithelial cells. Journal of Steroid Biochemistry and Molecular Biology 73(5):265-270.
25. Pasqualini JR, Chetrite GS. 2005. Estorgen sulfotransferase in breast cancer, in Pacifici GM, Coughtrie MWH, editors. Human cytosolic sulfotransferases. Boca Raton, FL: CRC Press. p. 135-156.
26. Pfeiffer E, Treiling CR, Hoehle SI, Metzler M. 2005. Isoflavones modulate the glucuronidation of estradiol in human liver microsomes. Carcinogenesis 26(12):2172-2178.
27. Russo J, Russo IH. 2006. The role of estrogen in the initiation of breast cancer. Journal of Steroid Biochemistry and Molecular Biology 102(1-5):89-96.
28. Soars MG, Ring BJ, Wrighton SA. 2003. The effect of incubation conditions on the enzyme kinetics of UDP-glucuronosyltransferases. Drug Metabolism and Disposition 31(6):762-767.
29. Ung D, Nagar S. 2007. Variable sulfation of dietary polyphenols by recombinant human sulfotransferase (SULT) 1A1 genetic variants and SULT1E1. Drug Metabolism and Disposition 35(5):740-746.
30. Zhang H, Varlamova O, Vargas FM, Falany CN, Leyh TS. 1998. Sulfuryl transfer: the catalytic mechanism of human estrogen sulfotransferase. Journal of Biology and Chemistry 273(18):10888-10892.